IPSEN (OTCMKTS:IPSEY – Get Free Report) saw an uptick in trading volume on Tuesday . 10,267 shares traded hands during mid-day trading, an increase of 447% from the previous session’s volume of 1,878 shares.The stock last traded at $45.91 and had previously closed at $47.60.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on the stock. Zacks Research raised shares of IPSEN to a “hold” rating in a research note on Friday, May 29th. Jefferies Financial Group cut shares of IPSEN from a “hold” rating to a “moderate sell” rating in a research note on Sunday, August 2nd. Barclays downgraded IPSEN from an “equal weight” rating to an “underweight” rating in a report on Tuesday. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Finally, HC Wainwright reiterated a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, IPSEN currently has an average rating of “Reduce”.
View Our Latest Stock Report on IPSEN
IPSEN Stock Performance
About IPSEN
Ipsen SA is a France-based biopharmaceutical company that develops and commercializes specialty medicines for serious diseases. Its primary focus areas are oncology, rare diseases and neuroscience, with research and development activities aimed at addressing conditions that often have limited treatment options.
The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected neurological and muscular conditions, and oncology treatments including Cabometyx and Onivyde.
Featured Stories
- Five stocks we like better than IPSEN
- Palantir’s New U.S. Army Contract Brings It Closer to Owning the Full Battlefield System
- Life Time Keeps Beating Expectations, But Insiders Are Selling Into Strength
- Sezzle’s BNPL Growth Is Working, But the Stock Comes With a Catch
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
Receive News & Ratings for IPSEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN and related companies with MarketBeat.com's FREE daily email newsletter.
